Bullish Case: Known: PACB ~$1.63 and calls lead puts. The PACB term structure is backwardated, but IV trends down across later maturities—consistent with mean reversion after the mid‑2026 “uncertainty hump.” The return-surface’s brightest bands sit near small moves (≈−20% to +20%). If SPRQ‑Nx/Revio consumables show accel in the next earnings, upside skew improves; my earlier $~1.10 bearish timing didn’t materialize.

Bearish Case: Known: PACB IV is extremely high and concentrated in near-dated options; backwardation signals traders expect another near-term negative repricing. The return-surface still shows meaningful likelihood in deep drawdown regions (≈−30% to −60%) over multi-quarter holds. SPY’s volatility surface retains downside skew on lower strikes across the next months, which tends to spill into risky biotech. A consumables/adoption miss or financing/dilution would likely pull PACB back toward ~$1.1–$1.2.

Potential Outcomes:

1. 48%: −5..+8% ($1.55–$1.76) as mean-reversion after IV hump.
2. 25%: −25..−40% ($0.98–$1.23) if Revio/Vega consumables miss guidance.
3. 17%: +20..+35% ($1.96–$2.20) if SPRQ‑Nx scaling shows accel.
4. 7%: ~$0.80 (−50%) on dilution/financing; cash-runway update confirms.
5. 3%: $2.60+ (+60%) on acquisition/major contract; LOI/terms confirm.

June 05, 2026